Latest "Vivos Therapeutics" News Stories - Page: 20

20:34 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Vivos Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Vivos Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Vivos Therapeutics for you to read. Along with our medical data and news we also list Vivos Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Vivos Therapeutics Companies for you to search.

Showing "Vivos Therapeutics" News Articles 476–500 of 7,800+

Probably Relevant

Gotham Therapeutics raises $54mm in Series A round

Gotham Therapeutics Corp. (treatments for autoimmune and neurodegenerative diseases and cancer) raised $54mm through its Seri...

United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement

United Therapeutics (Nasdaq: UTHR) and MannKind (Nasdaq: MNKD) announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. As quoted in the press release: As previously announced, th...

ACRX Nears D-day, TRVN On Watch, All's Well With CRSP, TearLab Disappointed

Today's Daily Dose brings you news about FDA staffers' comments on AcelRx Pharma's pain drug candidate Dsuvia; Audentes Therapeutics' stock offering; FDA lifting clinical hold on CRISPR Therapeutics' investigational drug; TearLab's disappointment, and Trevena's much-awaited regulatory catalyst.

BridgeBio-Backed CoA Therapeutics Challenges Retrophin In Genetic Disorder PKAN

Emerging Company Profile: CoA Therapeutics plans to start a Phase I study of a CoA modulator in the rare, genetic...    

Just What We Were Looking For: Roche Pays €70m For Preclinical Anti-CD25 Asset

Roche acquires Tusk Therapeutics of the UK for its lead asset; its other activities will continue as Black Belt Therapeutics...   

G1 Therapeutics nets $170mm through public offering

G1 Therapeutics Inc. netted $170mm through the public sale of 3mm common shares at $60. The company develops drugs for cancer...

IFM Therapeutics Launches IFM Due, Its Second Subsidiary Aimed at Parkinson’s and NASH

IFM Therapeutics is launching its second subsidiary in less than a year. This morning, the Boston-based company, launched IFM Due (pronounced du-way), a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases like NASH, lupus and Parkinson’s.

Bone Therapeutics: A unique approach to the development of cell therapy products for bone fracture repair & fracture prevention.

Bone Therapeutics is a biotechnology company with a unique approach to the development of cell therapy products for bone fracture repair and fracture prevention. Bone Therapeutics is creating a new and unique treatment approach using differentiated bone-forming cells administered via a minimally invasive percutaneous procedure, that is expected to offer significant benefits over the current stand...

Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock

CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of 2,604,167 shares of its common … Continue reading →

Sangamo Therapeutics completes acquisition of TxCell

Sangamo Therapeutics, Inc. has announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market.

Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs

Abeona Therapeutics (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced key pipeline updates during the Company’s 2018 R&D Day. As quoted in the press release: “The important clinical and preclinical updates we shared today further establish Abeona’s pathway to br...

Smith & Nephew buys Osiris Therapeutics in deal valued at $660mm

Expanding its wound healing and tissue repair portfolio, Smith & Nephew PLC is paying $19 per share in cash (a 7% premium bas...

Bayer Bosses Beg Risk-Averse Europe To Rethink

The German group believes it is going to be at the forefront of development in the cell and gene therapy...   

First patient dosed in Gyroscope Therapeutics’ AMD study

Gyroscope Therapeutics has announced that the first patient has been dosed in its Phase I/II FOCUS study for dry age-related macular degeneration (AMD).

Karus Therapeutics CEO Simon Kerry discusses the company's focus on PI3 Kinase and HDAC6 inhibitor programmes.

Simon Kerry the CEO of the Oxfordshire based company Karus Therapeutics, talks with Fintan Walton about the company's work to develop innovative medicines for the treatment of inflammatory disease and cancer.

Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA

Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced findings from three post-hoc analyses of data from the Phase 3 clinical trial of LUXTURNA (voretigene neparvovec-rzyl) at the American Academy of Ophthalmology Annual Meeting in Chicago. As quoted in the press release: LUXTURNA is R...

10 RNA Therapeutics Companies To Watch In 2019 …

10 RNA Therapeutics Companies To Watch In 2019 …

Agile Therapeutics reveals data from comparative wear study on its contraceptive patch Twirla

Agile Therapeutics Inc (NASDAQ:AGRX) CEO Al Altomari sat down with Proactive Investors at the BIO CEO and Investor Conference in New York. Agile's product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.

Allergy Therapeutics celebrating 20 years of growth and innovation

Allergy Therapeutics PLC's (LON:AGY) CEO Manuel Llobet and chief financial officer Nick Wykeman discuss with Proactive London's Andrew Scott the group's results for the six months to December 2018. The company saw turnover rise 10.6% to £46.7mln in the period, up from £42.2mln a year earlier. 2019 is Allergy's 20th anniversary since they spun out of GlaxoSmithKline.

Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million. And like Juno, Allogene is working with a live immune-cell treatment called CAR-T, but it is harvesting cells […]

Acorda Therapeutics Has One Bad Week With Loss of Patents and Delayed FDA Review

Acorda Therapeutics’ week started off badly and has only gotten worse. It started off with the loss of an appeal for some of its Ampyra patents and has ended with the U.S. FDA's decision to delay a ruling for its Parkinson’s disease treatment.

Revance Therapeutics' Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

More Short Term Downside Ahead For Emerald Health Therapeutics And Still Bullish?

In our Emerald Health Therapeutics stock forecast 2019 we tipped this cannabis stock as a great buy opportunity for 2019. However, its price has been falling recently. There is even more downside a...

Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline ...

SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline Read more...

Sarepta Therapeutics wird vom Markt unterschätzt!

New York ( - Sarepta Therapeutics-Aktienanalyse der Analysin Alethia Young von Cantor Fitzgerald: Analyst Alethia Young vom Investmenthaus Cantor Fitzgerald bestätigt laut einer ...

Quick Search


News Quicklinks